Histone modifications and chromatin organization in prostate cancer

Epigenomics

Volumn 2, Issue 4, 2010, Pages 551-560

  Chen, Zhong ^a   Wang, Liguo ^b   Wang, Qianben ^a   Li, Wei ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

bioinformatics; CHIA PET; ChIP seq; chromatin organization; epigenome; Hi C; histone modification; next generation sequencing; prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; HISTONE;

CHROMATIN ASSEMBLY AND DISASSEMBLY; DNA METHYLATION; ENHANCER REGION; EPIGENETICS; GENE ACTIVATION; GENE CONTROL; GENE EXPRESSION; GENE FUSION; GENE MUTATION; GENE REPRESSION; GENE SILENCING; GENETIC ANALYSIS; HUMAN; NUCLEOSOME; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN MODIFICATION; PROTO ONCOGENE; REVIEW; TUMOR SUPPRESSOR GENE;

BIOLOGICAL MARKERS; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, TUMOR SUPPRESSOR; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HISTONES; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 77955455559     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.10.31     Document Type: Review

References (90)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J. Clin. 59(4), 225-249 (2009).
2. Heinlein CA, Chang C: Androgen receptor in prostate cancer. Endocr. Rev. 25(2), 276-308 (2004).
3. Dehm SM, Tindall DJ: Androgen receptor structural and functional elements: role and regulation in prostate cancer. Mol. Endocrinol. 21(12), 2855-2863 (2007).
4. Feldman BJ, Feldman D: The development of androgen-independent prostate cancer. Nat. Rev. Cancer 1(1), 34-45 (2001).
5. Debes JD, Tindall DJ: Mechanisms of androgen-refractory prostate cancer. N. Engl. J. Med. 351(15), 1488-1490 (2004).
6. Cooper CS, Foster CS: Concepts of epigenetics in prostate cancer development. Br. J. Cancer 100(2), 240-245 (2009).
7. Diaw L, Woodson K, Gillespie JW: Prostate cancer epigenetics: a review on gene regulation. GeneRegul. Syst. Biol. 1, 313-325 (2007).
8. Dobosy JR, Roberts JL, Fu VX, Jarrard DF: The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia. J. Urol. 177(3), 822-831 (2007).
9. Li LC: Epigenetics of prostate cancer. Front. Biosci. 12, 3377-3397 (2007).
10. Bernstein BE, Meissner A, Lander ES: The mammalian epigenome. Cell 128(4), 669-681 (2007).
11. Probst AV, Dunleavy E, Almouzni G: Epigenetic inheritance during the cell cycle. Nat. Rev. Mol. Cell. Biol. 10(3), 192-206 (2009).
12. Johannes F, Colot V, Jansen RC: Epigenome dynamics: a quantitative genetics perspective. Nat. Rev. Genet. 9(11), 883-890 (2008).
13. Ting AH, Mcgarvey KM, Baylin SB: The cancer epigenome - components and functional correlates. Genes Dev. 20(23), 3215-3231 (2006).
14. Nelson WG, Yegnasubramanian S, Agoston AT et al.: Abnormal DNA methylation, epigenetics, and prostate cancer. Front. Biosci. 12, 4254-4266 (2007).
15. Schulz WA, Hatina J: Epigenetics of prostate cancer: beyond DNA methylation. J. Cell. Mol. Med. 10(1), 100-125 (2006).
16. Barski A, Cuddapah S, Cui K et al.: High-resolution profiling of histone methylations in the human genome. Cell 129(4), 823-837 (2007).
17. Mikkelsen TS, Ku M, Jaffe DB et al.: Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature 448(7153), 553-560 (2007).
18. Wang Z, Zang C, Rosenfeld JA et al.: Combinatorial patterns of histone acetylations and methylations in the human genome. Nat. Genet. 40(7), 897-903 (2008).
19. Lister R, Pelizzola M, Dowen RH et al.: Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 462(7271), 315-322 (2009).
20. Meissner A, Mikkelsen TS, Gu H et al.: Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature 454(7205), 766-770 (2008).
21. Schones DE, Cui K, Cuddapah S et al.: Dynamic regulation of nucleosome positioning in the human genome . Cell 132(5), 887-898 (2008).
22. Alekseyenko AA, Peng S, Larschan E et al.: A sequence motif within chromatin entry sites directs msl establishment on the drosophila X chromosome. Cell 134(4), 599-609 (2008).
23. Sultan M, Schulz MH, Richard H et al.: A global view of gene activity and alternative splicing by deep sequencing of the human transcriptome. Science 321(5891), 956-960 (2008).
24. Bammler T, Beyer RP, Bhattacharya S et al.: Standardizing global gene expression analysis between laboratories and across platforms. Nat. Methods 2(5), 351-356 (2005).
25. He HH, Meyer CA, Shin H et al.: Nucleosome dynamics define transcriptional enhancers. Nat. Genet. 42(4), 343-347 (2010).
26. Li H, Ruan J, Durbin R: Mapping short DNA sequencing reads and calling variants using mapping quality scores. Genome Res. 18(11), 1851-1858 (2008).
27. Zhang Y, Liu T, Meyer CA et al.: Model- based analysis of chip-seq (macs). Genome Biol. 9(9), R137 (2008).
28. Rozowsky J, Euskirchen G, Auerbach RK et al. : Peakseq enables systematic scoring of ChlP-seq experiments relative to controls. Nat. Biotechnol. 27(1), 66-75 (2009).
29. Hillier LW, Marth GT, Quinlan AR et al.: Whole-genome sequencing and variant discovery in c. Elegans. Nat. Methods 5(2), 183-188 (2008).
30. Van Steensel B: Mapping of genetic and epigenetic regulatory networks using microarrays. Nat. Genet. 37(Suppl.), S18-S24 (2005).
31. Scacheri PC, Davis S, Odom DT et al.: Genome-wide analysis of menin binding provides insights into men1 tumorigenesis. PLoS Genet. 2(4), E51 (2006).
32. Yang A, Zhu Z, Kapranov P et al.: Relationships between p63 binding, DNA sequence, transcription activity, and biological function in human cells. Mol. Cell 24(4), 593-602 (2006).
33. Krig SR, Jin VX, Bieda MC et al.: Identification of genes directly regulated by the oncogene znf217 using chromatin immunoprecipitation (ChlP)-ChlP assays. J. Biol. Chem. 282(13), 9703-9712 (2007).
34. Martone R, Euskirchen G, Bertone P et al.: Distribution of NF-kb-binding sites across human chromosome 22. Proc. Natl Acad. Sci. USA 100(21), 12247-12252 (2003).
35. Lieberman-Aiden E, Van Berkum NL, Williams L et al.: Comprehensive mapping of long-range interactions reveals folding principles of the human genome. Science 326(5950), 289-293 (2009).
36. Fullwood MJ, Liu MH, Pan YF et al.: An oestrogen-receptor-a-bound human chromatin interactome. Nature 462(7269), 58-64 (2009).
37. Kouzarides T: Chromatin modifications and their function. Cell 128(4), 693-705 (2007).
38. Martin C, Zhang Y: The diverse functions of histone lysine methylation. Nat. Rev. Mol. Cell. Biol. 6(11), 838-849 (2005).
39. Struhl K: Histone acetylation and transcriptional regulatory mechanisms. Genes Dev. 12(5), 599-606 (1998).
40. Hu X, Lazar MA: Transcriptional repression by nuclear hormone receptors. Trends Endocrinol. Metab. 11(1), 6-10 (2000).
41. Wang Q, Carroll JS, Brown M: Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking. Mol. Cell 19(5), 631-642 (2005).
42. Shang Y, Myers M, Brown M: Formation of the androgen receptor transcription complex. Mol. Cell 9(3), 601-610 (2002).
43. Kang Z, Janne OA, Palvimo JJ: Coregulator recruitment and histone modifications in transcriptional regulation by the androgen receptor. Mol. Endocrinol. 18(11), 2633-2648 (2004).
44. Heemers HV, Tindall DJ: Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the ar transcriptional complex. Endocr. Rev. 28(7), 778-808 (2007).
45. Yamane K, Toumazou C, Tsukada Y et al.: JHDM2A, a JmjC-containing H3K9 demethylase, facilitates transcription activation by androgen receptor. Cell 125(3), 483-495 (2006).
46. Wissmann M, Yin N, Muller JM et al.: Cooperative demethylation by JmjD2c and LSD1 promotes androgen receptor-dependent gene expression. Nat. Cell Biol. 9(3), 347-353.
47. Metzger E, Wissmann M, Yin N et al.: LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 437(7057), 436-439 (2005).
48. Van Ree JH, Jeganathan KB, Malureanu L, Van Deursen JM: Overexpression of the E2 ubiquitin-conjugating enzyme UBCH10 causes chromosome missegregation and tumor formation. J. Cell. Biol. 188(1), 83-100 (2010).
49. Wang Q, Li W, Zhang Y et al.: Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 138(2), 245-256 (2009).
50. Bernstein BE, Mikkelsen TS, Xie X et al.: A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 125(2), 315-326 (2006).
51. Roh TY, Cuddapah S, Cui K, Zhao K: The genomic landscape of histone modifications in human T cells. Proc. Natl Acad. Sci. USA 103(43), 15782-15787 (2006).
52. Wei G, Wei L, Zhu J et al.: Global mapping of H3K4me3 and H3K27me3 reveals specificity and plasticity in lineage fate determination of differentiating CD4+ T cells. Immunity 30(1), 155-167 (2009).
53. Ke XS, Qu Y, Rostad K et al.: Genome-wide profiling of histone H3 lysine 4 and lysine 27 trimethylation reveals an epigenetic signature in prostate carcinogenesis. PLoS One 4(3), E4687 (2009).
54. Schones DE, Zhao K: Genome-wide approaches to studying chromatin modifications. Nat. Rev. Genet. 9(3), 179-191 (2011)..
55. Wang Z, Schones DE, Zhao K: Characterization of human epigenomes. Curr. Opin. Genet. Dev. 19(2), 127-134 (2009).
56. Heintzman ND, Stuart RK, Hon G et al.: Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat. Genet. 39(3), 311-318 (2007).
57. Heintzman ND, Hon GC, Hawkins RD et al.: Histone modifications at human enhancers reflect global cell-type-specific gene expression. Nature 459(7243), 108-112 (2009).
58. Yu J, Yu J, Rhodes DR et al.: A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res. 67(22), 10657-10663 (2007).
59. Kondo Y, Shen L, Cheng AS et al.: Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat. Genet. 40(6), 741-750 (2008).
60. Yu J, Cao Q, Mehra R et al.: Integrative genomics analysis reveals silencing of p-adrenergic signaling by polycomb in prostate cancer. Cancer Cell 12(5), 419-431 (2007).
61. Cao R, Zhang Y: The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. Curr. Opin. Genet. Dev. 14(2), 155-164 (2004).
62. Bryant RJ, Winder SJ, Cross SS, Hamdy FC, Cunliffe VT: The polycomb group protein EZH2 regulates actin polymerization in human prostate cancer cells. Prostate 68(3), 255-263 (2008).
63. Varambally S, Dhanasekaran SM, Zhou M et al.: The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419(6907), 624-629 (2002).
64. Varambally S, Cao Q, Mani RS et al.: Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 322(5908), 1695-1699 (2008).
65. Seligson DB, Horvath S, Shi T et al.: Global histone modification patterns predict risk of prostate cancer recurrence. Nature 435(7046), 1262-1266 (2005).
66. Zhou LX, Li T, Huang YR, Sha JJ, Sun P, Li D: Application of histone modification in the risk prediction of the biochemical recurrence after radical prostatectomy. Asian J. Androl. 12(2), 171-179 (2010).
67. Seligson DB, Horvath S, Mcbrian MA et al.: Global levels of histone modifications predict prognosis in different cancers. Am. J. Pathol. 174(5), 1619-1628 (2009).
68. Ellinger J, Kahl P, Von Der Gathen J et al.: Global levels of histone modifications predict prostate cancer recurrence. Prostate 70(1), 61-69 (2010).
69. Henikoff S: Nucleosome destabilization in the epigenetic regulation of gene expression. Nat. Rev. Genet. 9(1), 15-26 (2008).
70. Ling JQ, Hoffman AR: Epigenetics of long-range chromatin interactions. Pediatr. Res. 61(5 Pt 2), 11R-16R (2007).
71. Lin JC, Jeong S, Liang G et al.: Role of nucleosomal occupancy in the epigenetic silencing of the MLH1 CpG island. Cancer Cell 12(5), 432-444 (2007).
72. Choi JK, Bae JB, Lyu J, Kim TY, Kim YJ: Nucleosome deposition and DNA methylation at coding region boundaries. Genome Biol. 10(9), R89 (2009).
73. Bondarenko VA, Steele LM, Ujvari A et al.: Nucleosomes can form a polar barrier to transcript elongation by RNA polymerase II. Mol. Cell24(3), 469-479 (2006).
74. Kornblihtt AR: Chromatin, transcript elongation and alternative splicing. Nat. Struct. Mol. Biol. 13(1), 5-7 (2006).
75. Jia L, Berman BP, Jariwala U et al.: Genomic androgen receptor-occupied regions with different functions, defined by histone acetylation, coregulators and transcriptional capacity. PLoS One 3(11), E3645 (2008).
76. Takayama K, Kaneshiro K, Tsutsumi S et al.: Identification of novel androgen response genes in prostate cancer cells by coupling chromatin immunoprecipitation and genomic microarray analysis. Oncogene 26(30), 4453-4463 (2007).
77. Wang Q, Li W, Liu XS et al.: A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol. Cell 27(3), 380-392 (2007).
78. Bolton EC, So AY, Chaivorapol C, Haqq CM, Li H, Yamamoto KR: Cell- and gene-specific regulation of primary target genes by the androgen receptor. Genes Dev. 21(16), 2005-2017 (2007).
79. Cairns BR: The logic of chromatin architecture and remodelling at promoters. Nature 461(7261), 193-198 (2009).
80. Gondor A, Ohlsson R: Chromosome crosstalk in three dimensions. Nature 461(7261), 212-217 (2009).
81. Dekker J: Gene regulation in the third dimension. Science 319(5871), 1793-1794 (2008).
82. Li T, Hu JF, Qiu X et al.: CTCF regulates allelic expression of IGF2 by orchestrating a promoter-polycomb repressive complex 2 intrachromosomal loop. Mol. Cell Biol. 28(20), 6473-6482 (2008).
83. Murrell A, Heeson S, Reik W: Interaction between differentially methylated regions partitions the imprinted genes IGF2 and H19 into parent-specific chromatin loops. Nat. Genet. 36(8), 889-893 (2004).
84. Kurukuti S, Tiwari VK, Tavoosidana G et al.: CTCF binding at the H19 imprinting control region mediates maternally inherited higher-order chromatin conformation to restrict enhancer access to IGF2. Proc. Natl Acad. Sci. USA 103(28), 10684-10689 (2006).
85. Dekker J, Rippe K, Dekker M, Kleckner N: Capturing chromosome conformation. Science 295(5558), 1306-1311 (2002).
86. Clark JP, Cooper CS: ETS gene fusions in prostate cancer. Nat. Rev. Urol. 6(8), 429-439 (2009).
87. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM: Recurrent gene fusions in prostate cancer. Nat. Rev. Cancer8(7), 497-511 (2008).
88. Mani RS, Tomlins SA, Callahan K et al.: Induced chromosomal proximity and gene fusions in prostate cancer. Science 326(5957), 1230 (2009).
89. Lin C, Yang L, Tanasa B et al.: Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell 139(6), 1069-1083 (2009).
90. Horner RL, Krapcho M, Neyman N et al.: SEER Cancer Statistics Review, 1975-2006, National Cancer Institute (2009)